AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02968758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparison between GenePOC PCR and Reference Method
Description: Stool specimen will be tested with the GenePOC CDiff test on the GenePOC Instrument. The results will be compared to Reference Method defined as direct and enriched culture method for observation of a toxigenic Clostridium difficile strain.
Study NCT00963859 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic surgery
Description: During radical cystectomy, robotic-assisted technique used to perform cystectomy and pelvic lymph node dissections. Each patient will undergo a second-look open lymph node dissection once the incision is made at the end for the urinary diversion.
Study NCT02811068 — intervention group
Intervention type: OTHER
Intervention: venepuncture
Description: single venepuncture
Study NCT01499836 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PVB
Description: paravertebral block
Study NCT01499836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVB
Description: paravertebral block
Study NCT00283296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endeavor
Description: Collapsible, forward folding manual wheelchair
Study NCT03278275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One injection of 68Ga-NOTA-AE105
Description: One injection of 68Ga-NORA-AE105
Study NCT03278275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Following injection of 68Ga-NOTA-AE105 the participants will be subjected to whole body PET/CT
Study NCT02528994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-serine
Description: Participants will take dietary serine supplementation daily
Study NCT02072668 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rivaroxaban
Description: Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
Study NCT02072668 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
Study NCT01164514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPG 7909
Description: CPG 7909 is a synthetic oligodeoxynucleotide used as an adjuvant and administered at 2 different dosages: 250 mcg and 500 mcg.
Study NCT01164514 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: J5-OMP Vaccine
Description: J5-OMP vaccine 10 mcg to be administered with and without CpG 7909 adjuvant 250 or 500 mcg, intramuscularly on Days 0, 29 and 59.
Study NCT01164514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: J5-OMP Vaccine
Description: J5-OMP vaccine 10 mcg to be administered with and without CpG 7909 adjuvant 250 or 500 mcg, intramuscularly on Days 0, 29 and 59.
Study NCT01164514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline.
Study NCT03238378 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Brachytherapy d 1-5(6)
Study NCT03238378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Hyperthermia d 2 + 5
Study NCT02512822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noninvasive Radiofrequency TruSculpt
Description: Heating subcutaneous fat up to 45℃ continuously at least 3 minutes without surface damage and induces adipocytes apoptosis.
Study NCT01542047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered intravenously over approximately 30 minutes on day 1 of each cycle. The dosage used will be 5 AUC for the first 5 cycles, and will be increased to 6 AUC for the sixth cycle.
Study NCT01542047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib will be administered orally at 200 to 800 mg/kg2. It will be given either on days 1 through 21 of each 3-week cycle, or if needed, it will be given on days 3 through 19.
Study NCT00284947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basiliximab
Description: 40 mg once every 28 days intravenously for 24 weeks
Study NCT00284947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF/EC-MPS
Description: 1g MMF or 720mg EC-MPS p.o twice daily
Study NCT00284947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Oral corticosteroids, equivalent to prednisone p.o, ≥ 5mg daily or ≥ 10mg on alternate days
Study NCT03264326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Training
Description: Delfi Personalized Tourniquet System occludes 80% venous pressure during lower extremity exercise.
Study NCT03264326 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Blood Flow Restriction Training
Description: Delfi Personalized Tourniquet System occlude 20 mmHG venous pressure during lower extremity exercise as a sham treatment.
Study NCT03264326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise
Description: Subjects perform eccentric calf lowering off a step for 90 repetitions twice daily.
Study NCT03264326 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Eccentric Exercise
Description: Subjects perform eccentric calf lowering off a step for 90 repetitions twice daily.
Study NCT00628420 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ACP-104
Description: 25mg, 75mg, 125mg, 175mg, 225mg, or 275mg once a day for 2 weeks
Study NCT00628420 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ACP-104
Description: Patient will be given either 50mg, 100mg, 150mg, 200mg, 250mg, or 300mg daily for 2 weeks
Study NCT00628420 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: patients will be given a placebo: 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, or 300mg (to match the doses given) daily for 2 weeks.
Study NCT03350594 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Family Therapy
Description: Patient will have 10 sessions of Systemic Family Therapy during 12 months with his/her family.
Study NCT03350594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Family Therapy
Description: Patient and his/fer family will have 10 sessions of Multiple Family Therapy during 12 months.
Study NCT00570986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two injections at weeks 0 and 4. One injection at week 8. At week 12, arm is rerandomized to placebo every 4 weeks.
Study NCT00570986 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ABT-874
Description: 200mg at week 0 and week 4. 100mg at week 8. On week 12, arm is rerandomized to 100mg every 4 weeks.
Study NCT00570986 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ABT-874
Description: 100mg every 12 weeks.
Study NCT03798951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: The patients included in the treatment group will follow a prehabilitation program, based on a physiotherapist, nutritionist and psychologist evaluation. All the treatments will be tailored according the characteristics of each single patient.~The program will have a duration of, at least, 4 weeks.
Study NCT04470154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage I:HSK21542 0.05 μg/kg
Description: Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
Study NCT04470154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage I:HSK21542 0.15 μg/kg
Description: Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
Study NCT04470154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage I:HSK21542 0.30 μg/kg
Description: Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
Study NCT04470154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage I:HSK21542 0.80 μg/kg
Description: Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
Study NCT04470154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage II:HSK21542 0.3 μg/kg
Description: Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
Study NCT04470154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage II:HSK21542 0.6 μg/kg
Description: Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
Study NCT03410706 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban(Xarelto, BAY 59-7939)
Description: The dosage and the anticoagulation duration is decided by investigators. As list in product information, the PE treatment dosage of rivaroxaban is 15mg bid for first 21 days and then 20mg qd. If CrCl is 30-49 ml/min and bleeding risk is over VTE recurrence risk, 20mg qd can be replaced with 15mg qd.
Study NCT01955135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 1mg/kg bolus intravenous, 0.25mg/kg/hour intravenous for maintenance of sedation
Study NCT01955135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: anesthesia was induced using 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen; Anesthesia was maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen
Study NCT01955135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 1 mg/kg propofol as a bolus for induction. The patients then received an infusion of 100-150 mcg/kg/min propofol
Study NCT04278599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Zinc supplementation
Description: In the test group, the patients will be administered Zinc Acetate tablets (equivalent to 30 mg of elemental zinc/day) for 6 weeks from the baseline. They will also be will be administered, topical corticosteroid paste- Triamcinolone acetonide- 0.1%, to be applied thrice a day till the lesions disappeared and the dosage will be tapered accordingly.The patients will be instructed to take the tablets and apply the paste after meals.The patients will be kept on a monthly follow-up for 3 months.
Study NCT04278599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo supplementation
Description: In the control group, the patients will be administered Placebo tablets for 6 weeks from the baseline. They will also be administered, topical corticosteroid paste- Triamcinolone acetonide- 0.1%, to be applied thrice a day till the lesions disappeared and the dosage will be tapered accordingly.The patients will be instructed to take the tablets and apply the paste after meals.The patients will be kept on a monthly follow-up for 3 months.
Study NCT01456884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live guitar and vocal music therapy
Description: Live guitar and vocal music therapy. Subject is passive recipient for 30 minutes.
Study NCT01456884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vibroacoustic Music Therapy
Description: 30 minutes using vibroacoustic mat.
Study NCT04032964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNF
Description: L19TNF 13 µg/kg i.v. will be administered on day 1, 3 and 5 of each 21-day cycle
Study NCT04032964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXORUBICIN
Description: Doxorubicin 75 mg/m2 will be administered on day 1 of each 21-day cycle
Study NCT04322526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 Mg Oral Tablet
Description: Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: \~1 hour; duration: \~24 hours).
Study NCT04322526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone 50 Mg Oral Tablet
Description: Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: \~1 hour; duration: \~24 hours).
Study NCT04322526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo tablet that has no inherent power to produce an effect. In the inert pill condition, participants will receive an oral placebo tablet.
Study NCT04322526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablet that has no inherent power to produce an effect. In the inert pill condition, participants will receive an oral placebo tablet.
Study NCT03146585 — intervention group
Intervention type: DEVICE
Intervention: PBR assessment
Description: Sublingual microcirculation will be investigated by specialized handheld videomicroscopy device for PBR index.
Study NCT01850121 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Description: 5 mg/kg every 6 weeks during the first year and 3 mg/kg every 8 weeks during the second year. Concomitant treatment with methotrexate 7.5 mg/week.
Study NCT01457508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib (Infanrix hexa™)
Description: Three doses administered intramuscularly
Study NCT01457508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa-HBV-IPV (Infanrix penta™)
Description: Three doses administered intramuscularly
Study NCT01457508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib (Hiberix™)
Description: Three doses administered intramuscularly
Study NCT01873872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Theralac probiotic
Study NCT01873872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Culturelle probiotic
Study NCT01873872 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02667119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure with Contingency Management
Description: Prolonged Exposure therapy for posttraumatic stress disorder includes psychoeducation, breathing retraining, in vivo exposure, and imaginal exposure.~Contingency Management for substance abuse disorders: participants will have the chance to win prizes for each negative urine drug screen/breathalyzer provided.
Study NCT02667119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard care will consist of treatment as usual in a community-based substance use treatment center.
Study NCT02667119 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care will consist of treatment as usual in a community-based substance use treatment center.
Study NCT00549783 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A 900kD
Description: The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.~First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
Study NCT01767090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707
Description: Oral
Study NCT01767090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT01767090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin acetate
Description: subcutaneous
Study NCT01071304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: A single oral dose of midazolam 2 mg (1 mL of 2 mg/mL syrup) was given on Day -2 and Day 5.
Study NCT01071304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Description: Ridaforolimus 40 mg (4 x 10 mg tablets) oral once daily on Days 1 through 5.
Study NCT03200249 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative chemo-radiation with IG-IMRT dose escalation
Study NCT00935584 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physician training in patient-centered emr use
Description: This intervention was performed in between the pre-intervention (Baseline) clinic visit and post intervention clinic visit.
Study NCT02689635 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Restricted Diet
Description: Cardiac Diet, as defined by our Hospital Nutritional Services (containing less than 2000 mg sodium per day)
Study NCT02689635 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Diet
Description: Non-Cardiac Diet, as defined by our Hospital Nutritional Services
Study NCT03230461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compression depth
Study NCT00549783 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.~First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
Study NCT01775280 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Injection of Ytttrium-90 microspheres into the hepatic artery
Description: INjection of Y-90 particles into the hepatic artery using endovascular access
Study NCT00521066 — intervention group
Intervention type: DEVICE
Intervention: GYNECARE PROSIMA* Pelvic Floor Repair System
Description: procedure for pelvic organ prolapse
Study NCT02850120 — intervention group
Intervention type: PROCEDURE
Intervention: Tension-free vaginal tape (TVT)
Description: Surgical insertion of Tension-free vaginal tape (TVT) polypropylene mesh in the treatment of stress urinary incontinence.
Study NCT02850120 — intervention group
Intervention type: PROCEDURE
Intervention: Trans-obturator tape (TOT)
Description: Surgical insertion of Trans-obturator tape (TOT) polypropylene mesh in the treatment of stress urinary incontinence.
Study NCT02850120 — intervention group
Intervention type: PROCEDURE
Intervention: Suprapubic sling (SS)
Description: Surgical insertion of Suprapubic sling (SS) polypropylene mesh in the treatment of stress urinary incontinence.
Study NCT02335710 — intervention group
Intervention type: DEVICE
Intervention: Journey II BCS TKA
Study NCT02325557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADXS31-142
Description: ADXS31-142 IV infusion
Study NCT02325557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion
Study NCT02936167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ringer Lactate
Study NCT03846492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive brain stimulation modality that does not require general anesthesia or surgical implantation of a device. tDCS utilizes low intensity electrical current either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode. It uses 3 AAA batteries to deliver direct current via rubber electrodes enclosed in saline soaked sponges.
Study NCT03846492 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive brain stimulation modality that does not require general anesthesia or surgical implantation of a device. tDCS utilizes low intensity electrical current either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode. It uses 3 AAA batteries to deliver direct current via rubber electrodes enclosed in saline soaked sponges.
Study NCT03038061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients undergoing Laparoscopic Surgery
Description: Data are to be obtained at three phases at supine horizontal position (during spontaneous breathing, at mechanically ventilated patient under general anesthesia with muscle relaxation and at mechanically ventilated patient under general anesthesia with muscle relaxation during insufflation of carbon dioxide into the peritoneal cavity to achieve exposure during laparoscopic surgery).
Study NCT01484587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959
Description: CNTO 1959: type=range, unit=mg, number=10, 30, 100, 300, form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
Study NCT01484587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
Study NCT00687193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID, 3 blinded tablets administered BID for 12 weeks
Study NCT00687193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10mg BID, 3 blinded tablets administered BID for 12 weeks